Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18257482 | 0.96 | EPHX1 (0.60) | EPHX1POLBBTKSMN1; SMN2GAA | |
| SCHEMBL18994820 | 0.96 | EPHX1 (0.53) | EPHX1POLBBTKSMN1; SMN2GAA | |
| SCHEMBL22299790 | 0.95 | EPHX1 (0.58) | EPHX1POLBBTKSMN1; SMN2GAA | |
| SCHEMBL2951839 | 0.94 | EPHX1 (0.51) | EPHX1BTKSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2951842 | 0.94 | EPHX1 (0.51) | EPHX1BTKSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL5113769 | 0.88 | EPHX1 (0.73) | EPHX1BTKGAAALDH1A1MEN1 | |
| SCHEMBL5416045 | 0.87 | EPHX1 (0.70) | EPHX1BTKGAAALDH1A1MEN1 | |
| SCHEMBL19263939 | 0.84 | EPHX1 (0.66) | EPHX1BTKGAAALDH1A1MEN1 | |
| SCHEMBL5619433 | 0.84 | EPHX1 (0.60) | EPHX1BTKGAAALDH1A1MEN1 | |
| SCHEMBL24435431 | 0.80 | EPHX1 (0.65) | EPHX1GAAMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | EPHX1 810/4885POLB 4852/4885BTK 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.